News

We know that HER2-positive breast cancer has the potential to behave more aggressively, and it has a higher risk of returning post-treatment. Historically, that was something that we could only lament ...
FDA designates T-DXd plus pertuzumab as breakthrough therapy for HER2-positive metastatic breast cancer, promising improved survival rates for patients.
In late 2019, trastuzumab deruxtecan was approved for the treatment of metastatic HER2/neu-positive breast cancer based on a phase two single arm trial that showed an extremely high response rate ...
Omitting carboplatin could be an efficacious de-escalated neoadjuvant strategy in the presence of dual HER2 blockade for patients with HER2-positive early breast cancer,” said Kun Wang, MD, PhD.
The percentages of HER-2 NEU positive patients in these years was 15.7%, 16.0%, and 9.4% in 2015, 2016 and 2017 respectively. This represented a 6.6% drop in HER-2 NEU positive patients from 2016 to ...
Julie Fisher, MD, explains how she assesses HER2-positive breast cancer patients for treatment response, what side-effects can occur and how they can be managed. Julie Fisher, MD, ... Both pertuzumab ...
Of the 220 invasive cancers, 78 were node positive and 17 (22%) of these were HER-2/neu positive; 113 were node negative and 14 (12.5%) were HER-2/neu positive; in 29 cases axillary dissection was ...
RESULTS: HER-2/neu status was available for 651 patients with ER-positive disease; 650, 608, and 353 patients were assessed by IHC, PCR, and FISH, respectively. Approximately one half received ...
The German Institute for Quality and Efficiency in Health Care (IQWiG) has examined the pros and cons of biomarker-based ...
HER2-positive breast cancer is different from other breast cancer types, so your treatment won’t necessarily be the same as someone else who has a different form of breast cancer.
In patients with MBC and HER2/neu overexpression or HER2 amplification, a combination of the humanized anti-HER2 monoclonal antibody trastuzumab and a taxane, with or without carboplatin, has been ...